Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
G Morad, BA Helmink, P Sharma, JA Wargo - Cell, 2021 - cell.com
Unprecedented advances have been made in cancer treatment with the use of immune
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
checkpoint blockade (ICB). However, responses are limited to a subset of patients, and …
Risk factors and biomarkers for immune-related adverse events: a practical guide to identifying high-risk patients and rechallenging immune checkpoint inhibitors
A Chennamadhavuni, L Abushahin, N Jin… - Frontiers in …, 2022 - frontiersin.org
Immune-related adverse events (irAEs) are a range of complications associated with the use
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …
of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic …
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
Abstract Treatment with combined immune checkpoint blockade (CICB) targeting CTLA-4
and PD-1 is associated with clinical benefit across tumor types, but also a high rate of …
and PD-1 is associated with clinical benefit across tumor types, but also a high rate of …
A review of cancer immunotherapy: from the past, to the present, to the future
K Esfahani, L Roudaia, N Buhlaiga, SV Del Rincon… - Current …, 2020 - mdpi.com
A review of cancer immunotherapy: from the past, to the present, to the future Page 1 S87
Current Oncology, Vol. 27, Supp. 2, April 2020 © 2020 Multimed Inc. REVIEW ARTICLE A …
Current Oncology, Vol. 27, Supp. 2, April 2020 © 2020 Multimed Inc. REVIEW ARTICLE A …
Fundamental mechanisms of immune checkpoint blockade therapy
SC Wei, CR Duffy, JP Allison - Cancer discovery, 2018 - AACR
Immune checkpoint blockade is able to induce durable responses across multiple types of
cancer, which has enabled the oncology community to begin to envision potentially curative …
cancer, which has enabled the oncology community to begin to envision potentially curative …
Immune checkpoint inhibitor–related dermatologic adverse events
AN Geisler, GS Phillips, DM Barrios, J Wu… - Journal of the American …, 2020 - Elsevier
Immune checkpoint inhibitors have emerged as a pillar in the management of advanced
malignancies. However, nonspecific immune activation may lead to immune-related adverse …
malignancies. However, nonspecific immune activation may lead to immune-related adverse …
The immune contexture in cancer prognosis and treatment
Immunotherapy is currently the most rapidly advancing area of clinical oncology, and
provides the unprecedented opportunity to effectively treat, and even cure, several …
provides the unprecedented opportunity to effectively treat, and even cure, several …
CTLA-4: a moving target in immunotherapy
B Rowshanravan, N Halliday… - Blood, The Journal of …, 2018 - ashpublications.org
CD28 and CTLA-4 are members of a family of immunoglobulin-related receptors that are
responsible for various aspects of T-cell immune regulation. The family includes CD28 …
responsible for various aspects of T-cell immune regulation. The family includes CD28 …
Microneedles for painless transdermal immunotherapeutic applications
Immunotherapy has recently garnered plenty of attention to improve the clinical outcomes in
the treatment of various diseases. However, owing to the dynamic nature of the immune …
the treatment of various diseases. However, owing to the dynamic nature of the immune …
Moving towards personalized treatments of immune-related adverse events
K Esfahani, A Elkrief, C Calabrese, R Lapointe… - Nature reviews Clinical …, 2020 - nature.com
The enhancement of immune responses upon treatment with immune checkpoint inhibitors
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …
can have the desired outcome of reinvigorating antitumour immune surveillance, but often at …